Please use this identifier to cite or link to this item:
Title: Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
Author: Torres Martí, Antoni
Motos, Anna
Battaglini, Denise
Bassi, Gianluigi Li
Keywords: Bacteris gramnegatius
Unitats de cures intensives
Infeccions respiratòries
Gram-negative bacteria
Intensive care units
Respiratory infections
Issue Date: 17-Dec-2018
Publisher: BioMed Central
Abstract: Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.
Note: Reproducció del document publicat a:
It is part of: Critical Care, 2018, vol. 22, num. 1, p. 343
Related resource:
ISSN: 1364-8535
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
686795.pdf2.7 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons